Histone demethylase JARID1C/KDM5C regulates Th17 cells by increasing IL-6 expression in diabetic plasmacytoid dendritic cells

• Published in: JCI insight Vol. 9; no. 12
• Main Authors: Audu, Christopher O, Wolf, Sonya J, Joshi, Amrita D, Moon, Jadie Y, Melvin, William J, Sharma, Sriganesh B, Davis, Frank M, Obi, Andrea T, Wasikowski, Rachel, Tsoi, Lam C, Barrett, Emily C, Mangum, Kevin D, Bauer, Tyler M, Kunkel, Steven L, Moore, Beth B, Gallagher, Katherine A
• Format: Journal Article
• Language: English
• Published: United States American Society for Clinical Investigation 24.06.2024
• Subjects: Animals; Dendritic Cells - immunology; Dendritic Cells - metabolism; Female; Humans; Interleukin-17 - metabolism; Interleukin-6 - metabolism; Jumonji Domain-Containing Histone Demethylases - genetics; Jumonji Domain-Containing Histone Demethylases - metabolism; Male; Mice; Mice, Inbred C57BL; Th17 Cells - immunology; Th17 Cells - metabolism; Wound Healing - immunology; Epigenetics; Adaptive immunity; Inflammation; Immunology; Dendritic cells
• ISSN: 2379-3708; 2379-3708
• DOI: 10.1172/jci.insight.172959

Plasmacytoid dendritic cells (pDCs) are first responders to tissue injury, where they prime naive T cells. The role of pDCs in physiologic wound repair has been examined, but little is known about pDCs in diabetic wound tissue and their interactions with naive CD4+ T cells. Diabetic wounds are characterized by increased levels of inflammatory IL-17A cytokine, partly due to increased Th17 CD4+ cells. This increased IL-17A cytokine, in excess, impairs tissue repair. Here, using human tissue and murine wound healing models, we found that diabetic wound pDCs produced excess IL-6 and TGF-β and that these cytokines skewed naive CD4+ T cells toward a Th17 inflammatory phenotype following cutaneous injury. Further, we identified that increased IL-6 cytokine production by diabetic wound pDCs is regulated by a histone demethylase, Jumonji AT-rich interactive domain 1C histone demethylase (JARID1C). Decreased JARID1C increased IL-6 transcription in diabetic pDCs, and this process was regulated upstream by an IFN-I/TYK2/JAK1,3 signaling pathway. When inhibited in nondiabetic wound pDCs, JARID1C skewed naive CD4+ T cells toward a Th17 phenotype and increased IL-17A production. Together, this suggests that diabetic wound pDCs are epigenetically altered to increase IL-6 expression that then affects T cell phenotype. These findings identify a therapeutically manipulable pathway in diabetic wounds.